Engineered virus-hunter vaccine overcomes HBV immune tolerance - Top-Institutions - MDSpire

Engineered virus-hunter vaccine overcomes HBV immune tolerance

  • By

  • Xiaoqing Chen

  • Xue Liu

  • Tao Xu

  • Yalin Wang

  • Peng Wang

  • Han Liu

  • Yichao Jiang

  • Xiaojing Qin

  • Liang Zhang

  • Yueting Xiong

  • Jiancheng Ding

  • Yuanzhi Chen

  • Fentian Chen

  • Wenjing Ning

  • Hongye Zeng

  • Shiting Yang

  • Lin Xu

  • Tianying Zhang

  • Quan Yuan

  • Chao Liu

  • Wenxin Luo

  • Ningshao Xia

  • June 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University School of Medicine / The Johns Hopkins Hospital
    Johns Hopkins University School of Medicine / The Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Infectious Disease
    • Hepatology

  • #2

    University of Oxford – The Jenner Institute
    University of Oxford – The Jenner Institute

    Oxford, United Kingdom

    Key Differentiators

    • Infectious Disease
    • Vaccinology

  • #3

    Okayama University Hospital
    Okayama University Hospital

    Okayama, Japan

    Key Differentiators

    • Infectious Disease
    • Liver Transplantation

  • #4

    Grady Ponce de Leon Center
    Grady Ponce de Leon Center

    Atlanta, Georgia

    Key Differentiators

    • Infectious Disease
    • HIV Care

  • #5

    American Gastroenterological Association
    American Gastroenterological Association

    Bethesda, Maryland

    Key Differentiators

    • Gastroenterology
    • Infectious Disease

Original Source(s)

Engineered virus-hunter vaccine overcomes HBV immune tolerance

  • by Xiaoqing Chen, Xue Liu, Tao Xu, Yalin Wang, Peng Wang, Han Liu, Yichao Jiang, Xiaojing Qin, Liang Zhang, Yueting Xiong, Jiancheng Ding, Yuanzhi Chen, Fentian Chen, Wenjing Ning, Hongye Zeng, Shiting Yang, Lin Xu, Tianying Zhang, Quan Yuan, Chao Liu, Wenxin Luo, Ningshao Xia

  • June 1, 2026

Related Content

From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • by

  • June 1, 2026

  • 5 min
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial